Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation," a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014," S 2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 of the COMPETE Act of 2014," and in S 2260 "Expiring Provisions Improvement, Reform, and Efficiency Act of 2014 (or EXPIRE Act of 2014);" tax policy issues related to corporate inversions including S 2786 "Corporate Inverters Earning Stripping Reform Act of 2014" and HR 4679 & S 2360 "Stop Corporate Inversions Act of 2014" and S 2704 & HR 5278 "No Federal Contracts for Corporate Deserters Act of 2014;" and all provisions of HR 2835 and S 1647 "Restoring Access to Medication Act of 2013."
Issues related to foreign direct investment in the U.S. including all provisions of HR 2052 "Global Investment in American Jobs Act of 2013."
Duration: March 31, 2008
to
December 31, 2014
General Issues: Taxation/Internal Revenue Code , Economics/Economic Development , Health Issues , Medical/Disease Research/Clinical Labs , Trade (Domestic & Foreign)
Spending: about $775,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Treasury - Dept of
Related Foreign Entities:
sanofi-aventis SA (Paris, FRA); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2014
CANFIELD & ASSOCIATES, INC. terminated an engagement in which they represented Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) on Jan. 20, 2015.
Original Filing: 300704117.xml
Lobbying Issues
Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation," a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014," S 2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 of the COMPETE Act of 2014," and in S 2260 "Expiring Provisions Improvement, Reform, and Efficiency Act of 2014 (or EXPIRE Act of 2014);" tax policy issues related to corporate inversions including S 2786 "Corporate Inverters Earning Stripping Reform Act of 2014" and HR 4679 & S 2360 "Stop Corporate Inversions Act of 2014" and S 2704 & HR 5278 "No Federal Contracts for Corporate Deserters Act of 2014;" and all provisions of HR 2835 and S 1647 "Restoring Access to Medication Act of 2013."
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to foreign direct investment in the U.S. including all provisions of HR 2052 "Global Investment in American Jobs Act of 2013."
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
3rd Quarter, 2014
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 20, 2014.
Original Filing: 300684841.xml
Lobbying Issues
All provisions of HR 2052, "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Corporate tax reform; all provisions of H.R. 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in H.R. 4438 "American Research and Competitiveness Act of 2014", H.R. 3474 "Hire More Heroes Act of 2014", and H.R. 4 "Jobs for America Act"; S. 2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S.2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and H.R. 4679 & S. 2360 "Stop Corporate Inversions Act of 2014" and S. 2704 & H.R. 5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of H.R. 2835 and S. 1647 "Restoring Access to Medication Act of 2013"
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 15, 2014.
Original Filing: 300656897.xml
Lobbying Issues
All provisions of HR 2052, "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Corporate tax reform, including Chairman Camp's discussion draft legislation "Tax Reform Act of 2014;" all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation;" and maintaining the orphan drug tax credit; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014" and HR 3474 "Hire More Heroes Act of 2014;" and all provisions of HR 2835 and S 1647, "Restoring Access to Medication Act of 2013."
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 21, 2014.
Original Filing: 300643951.xml
Lobbying Issues
Corporate tax reform, including Chairman Camps discussion draft legislation Tax Reform Act of 2014; a strengthened and permanent U.S. R&D tax credit, and all provisions of HR 2835 and S 1647 Restoring Access to Medication Act of 2010."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of HR 2052 and S 1023, Global Investment in America Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
4th Quarter, 2013
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 13, 2014.
Original Filing: 300612808.xml
Lobbying Issues
General issues related to corporate income tax reform; a strengthened and permanent U.S. R&D tax credit; extending and maintaining the orphan drug tax credit; all provisions of HR 2835, Restoring Access to Medication Act of 2013
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of HR 2052 and S 1023, Global Investment in America Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
All provisions of HR 2049, School Access to Emergency Epinephrine Act."
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 22, 2013.
Original Filing: 300608083.xml
Lobbying Issues
General issues related to corporate income tax reform; a strengthened and permanent U.S. R&D tax credit; extending and maintaining the orphan drug tax credit; all provisions of HR 2835, Restoring Access to Medication Act of 2013
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of HR 2052 and S 1023, Global Investment in America Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
All provisions of HR 2049, School Access to Emergency Epinephrine Act; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 22, 2013.
Original Filing: 300584007.xml
Lobbying Issues
Extension of the U.S. R&D tax credit; All provisions of H.R. 475/Public Law 113-15, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines, to add quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of HR 2052 and S 1023 Global Investment in America Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to school access to emergency epinephrine.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300559405.xml
Lobbying Issues
Extension of the U.S. R&D tax credit; adding quadrivalent influenza vaccine formulation to Vaccine Injury Compensation Program
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to foreign direct investment in the United States
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to school access to emergency epinephrine.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 18, 2013.
Original Filing: 300535417.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and HR8, "American Taxpayer Relief Act of 2012;" adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against season influenza within the definitionof taxable vaccines."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S3274 and HR5910 "Global Investment in American Jobs Act of 2012"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
H.R. 3627 and S. 1884 School Access to Emergency Epinephrine Act all provisions.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 22, 2012.
Original Filing: 300517034.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and efforts to add Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S3274 and HR5910 "Global Investment in American Jobs Act of 2012"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
H.R. 3627 and S. 1884 School Access to Emergency Epinephrine Act all provisions.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 19, 2012.
Original Filing: 300493320.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R. 942, "The American Research and Competitiveness Act of 2011" and S. 1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)." Efforts to add Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of H.R. 5651, "Food and Drug Administration Reform Act of 2012" and S. 3187, "Food and Drug Administration Safety and Innovation Act."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S.3274 and H.R. 5910, "Global Investment in American Jobs Act of 2012."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
1st Quarter, 2012
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 13, 2012.
Original Filing: 300460197.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R. 942, "The American Research and Competitiveness Act of 2011" and S. 1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 19, 2012.
Original Filing: 300443704.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R. 942, "The American Research and Competitiveness Act of 2011" and S. 1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs including amendment No. 769 to H.R. 2112, "Consolidated and Further Continuing Appropriations Act, 2012."
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 20, 2011.
Original Filing: 300426073.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R. 942, "The American Research and Competitiveness Act of 2011" and S. 1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Awareness and issues related to patient access to atrial fibrillation care, including all provisions in H Res 295, "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease," and S Res 243"Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 20, 2011.
Original Filing: 300404140.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R.942, "The American Research and Competitiveness Act of 2011."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295, "Promoting Increased Awareness, Diagnosis, and Treatment of Atrial Fibrillation and to Address the High Morbidity and Mortality Rates and to Prevent Avoidable Hospitalizations Associated With This Disease."
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 20, 2011.
Original Filing: 300376488.xml
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in H.R.942, "The American Research and Competitiveness Act of 2011."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2010
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351055.xml
Lobbying Issues
Extension of the R&D tax credit (H.R. 4853, "Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010.")
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 20, 2010.
Original Filing: 300326222.xml
Lobbying Issues
Extension of the R&D tax credit (H.R. 4213, "American Jobs and Closing Tax Loopholes Act of 2010.")
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 19, 2010.
Original Filing: 300294127.xml
Lobbying Issues
Extension of the R&D tax credit (H.R. 4213, "American Jobs and Closing Tax Loopholes Act of 2010.")
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 20, 2010.
Original Filing: 300272236.xml
Lobbying Issues
Extension of the R&D tax credit including all such provisions in Section 111 of H.R. 4213, "Tax Extenders Act of 2009," H.R. 422, "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit" and S. 1203, "Grow Research Opportunities with Tax Credits' Help Act."
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246183.xml
Lobbying Issues
Extension of the R&D tax credit including all such provisions in Section 111 of H.R. 4123, "Tax Extenders Act of 2009," H.R. 422, "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit" and S. 1203, "Grow Research Opportunities with Tax Credits' Help Act." Issues releated to international tax treaties and the ratification of the Second Protocol to the Income Tax Treaty to the U.S. and France.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 20, 2009.
Original Filing: 300217816.xml
Lobbying Issues
Extension of the R&D tax credit including all such provisions in H.R. 422, "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit" and S. 1203, "Grow Research Opportunities with Tax Credits' Help Act." Issues releated to international tax treaties and the ratification of the Second Protocol to the Income Tax Treaty to the U.S. and France.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 20, 2009.
Original Filing: 300189954.xml
Lobbying Issues
Issues related to awareness of sanofi-aventis' Access to Medicines Program
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to tax treaties and ratification of the Second Protocol to the Tax Treaty Between the United States and France
Agencies Lobbied
Treasury - Dept of
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2009
In Q1, CANFIELD & ASSOCIATES, INC. did no lobbying for sanofi-aventis U.S. Inc. . The report was filed on April 20, 2009.
Original Filing: 300160960.xml
4th Quarter, 2008
In Q4, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Jan. 16, 2009.
Original Filing: 300124052.xml
Lobbying Issues
Issues related to the R&D tax credit
Issues related to the ongoing negotiations of a protocol to the United States-France Tax Treaty.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099465.xml
Lobbying Issues
Issues related to the R&D tax credit
Issues related to the ongoing negotiations of a protocol to the United States-France Tax Treaty.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on July 3, 2008.
Original Filing: 300060987.xml
Lobbying Issues
Issues related to the R&D tax credit.
Issues related to the ongoing negotiations of a protocol to the United States-France Tax Treaty.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, CANFIELD & ASSOCIATES, INC. lobbied for sanofi-aventis U.S. Inc. , earning $5,000. The report was filed on April 21, 2008.
Original Filing: 300051812.xml
Lobbying Issues
Issues related to the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
CANFIELD & ASSOCIATES, INC. filed a lobbying registration on April 17, 2008 to represent sanofi-aventis U.S. Inc., effective March 31, 2008.
Original Filing: 300044747.xml
Issue(s) they said they’d lobby about: issues related to the R&D tax credit; international tax issues; general trade issues .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...